About
At the Heart of Nanobody research
The VIB Nanobody Core incorporated at VUB at the heart of Nanobody discovery by Raymond Hamers in 1989. The Nanobody Core, as other research groups, are located near each other and still cross-polinate technical innovations. The VIB Nanobody Core is a reference center for Nanobodies and its excellence is nurtured by a devoted team of scientists internationally recognized as pioneers and major contributors to Nanobody technology and the state-of-the-art facilities.
Our Philosophy
We achieve high quality service by extensive support to our customers. Client customization and in-depth definition of the goals are our key factors.
The best modalities for the immunization of the antigen in question are used and the antigen is kept in the best possible shape during the panning and screening stages. Additional support is provided on how to best express, re-clone, purify and use the generated Nanobodies to obtain the goals. We deliver a new set of Nanobodies and provide the support to make the Nanobodies successful!
Our history
The VIB Nanobody Core was founded by the internationally reputed group which discovered the camelid heavy-chain antibodies and developed the Nanobody technology , and has contributed over 400 Nanobody-related peer-reviewed publications in high ranking journals and the establishment of several biotech companies.
Spinoff: Ablynx
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB).
Foundation of VIB Nanobody Service Facility
Nanobodies were recognized as a revolutionary discovery in the antibody field that VIB wants to make available to all its groups.
VIB Nanobody Core opens up Nanobody services to everyone
The VIB Nanobody Service Facility morphs into the VIB Nanobody Core and opens up it's doors to everyone needing Nanobody services: VIB labs, Academics from universities and Biotech companies. Our clients come from all over the world, from the USA to China.
Spinoff: Confo Therapeutics
Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.
Patented solution for Nb serum half-life extension
An anti-serum albumin Nb was developed with a good affinity for mouse, human, rat, cyno- and rhesus monkey serum albumin. It has excellent properties such as good expression yields, high solubility and stability and not interfering with the natural ligands of serum albumin. Available for licensing.